Mie University · Clinical Research and Development Center

Research keywordsケミカルバイオロジー・毒性学・線維化・化学遺伝学・腫瘍腎臓病学・薬剤性腎障害・薬学・医薬品安全性評価

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Successful use of brexpiprazole for Parkinson’s disease psychosis without adverse effects: a case report.
• Physicochemical Characterization of Tretinoin Tocoferil Emulsion and Povidone-Iodine Sugar Ointment Blend Developed for Improved Regulation of Wound Moisture
• Physicochemical properties of macrogol ointment and emulsion ointment blend developed for regulation of water absorption
• Sphingosine 1‑phosphate induced by hypoxia increases the expression of PAI‑1 in HepG2 cells via HIF‑1α.

• がん分子標的薬による腎障害の発現機序解明：BRAF阻害剤に着目した検討
• 分子標的薬の腎障害メカニズムの解明―大規模データから検出された新規リスクの検討―
• Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma
• 選択的BRAF阻害剤のポドサイト保護・毒性作用を決定付ける真の標的分子の同定

• Official profile